VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Functional class II, III or IV by the New York     │ Functional class II, III or IV by the New York     │     100 │
│ Heart Association (NYHA)                           │ Heart Association (NYHA)                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ischemic and nonischemic etiology                  │ Ischemic and nonischemic etiology                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of hypersensitivity or allergy to any of   │ History of hypersensitivity or allergy to any of   │     100 │
│ the study drugs, drugs of similar chemical         │ the study drugs, drugs of similar chemical         │         │
│ classes, ACE inhibitors (ACEIs), angiotensin II    │ classes, ACE inhibitors (ACEIs), angiotensin II    │         │
│ receptor blockers (ARBs), or neprilysin            │ receptor blockers (ARBs), or neprilysin            │         │
│ inhibitors, as well as known or suspected          │ inhibitors, as well as known or suspected          │         │
│ contraindications to the study drugs               │ contraindications to the study drugs               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous history of intolerance to recommended     │ Previous history of intolerance to recommended     │     100 │
│ target doses of ACEIs or ARBs                      │ target doses of ACEIs or ARBs                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known history of angioedema                        │ Known history of angioedema                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Requirement for treatment with both ACEIs and ARBs │ Requirement for treatment with both ACEIs and ARBs │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current acute decompensated heart failure          │ Current acute decompensated heart failure          │     100 │
│ (exacerbation of chronic heart failure manifested  │ (exacerbation of chronic heart failure manifested  │         │
│ by signs and symptoms that may require intravenous │ by signs and symptoms that may require intravenous │         │
│ therapy)                                           │ therapy)                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Symptomatic hypotension                            │ Symptomatic hypotension                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute coronary syndrome, stroke, transient         │ Acute coronary syndrome, stroke, transient         │     100 │
│ ischaemic attack, cardiac, carotid, or other major │ ischaemic attack, cardiac, carotid, or other major │         │
│ cardiovascular surgery, percutaneous coronary      │ cardiovascular surgery, percutaneous coronary      │         │
│ intervention, or carotid angioplasty within the 3  │ intervention, or carotid angioplasty within the 3  │         │
│ months                                             │ months                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Coronary or carotid artery disease likely to       │ Coronary or carotid artery disease likely to       │     100 │
│ require surgical or percutaneous intervention      │ require surgical or percutaneous intervention      │         │
│ within the 6 months                                │ within the 6 months                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Implantation of a cardiac resynchronization        │ Implantation of a cardiac resynchronization        │     100 │
│ therapy (CRT) device within 3 months or intent to  │ therapy (CRT) device within 3 months or intent to  │         │
│ implant a CRT                                      │ implant a CRT                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of heart transplant or on a transplant     │ History of heart transplant or on a transplant     │     100 │
│ list or with left ventricular (LV) assistance      │ list or with left ventricular (LV) assistance      │         │
│ device                                             │ device                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of severe pulmonary disease                │ History of severe pulmonary disease                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosis of peripartum- or chemotherapy-induced   │ Diagnosis of peripartum- or chemotherapy-induced   │     100 │
│ cardiomyopathy within the 12 months                │ cardiomyopathy within the 12 months                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documented untreated ventricular arrhythmia with   │ Documented untreated ventricular arrhythmia with   │     100 │
│ syncopal episodes within the 3 months              │ syncopal episodes within the 3 months              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Symptomatic bradycardia or second- or third-degree │ Symptomatic bradycardia or second- or third-degree │     100 │
│ atrioventricular block without a pacemaker         │ atrioventricular block without a pacemaker         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of haemodynamically significant mitral    │ Presence of haemodynamically significant mitral    │     100 │
│ and/or aortic valve disease, except mitral         │ and/or aortic valve disease, except mitral         │         │
│ regurgitation secondary to LV dilatation           │ regurgitation secondary to LV dilatation           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of other haemodynamically significant     │ Presence of other haemodynamically significant     │     100 │
│ obstructive lesions of the LV outflow tract,       │ obstructive lesions of the LV outflow tract,       │         │
│ including aortic and subaortic stenosis            │ including aortic and subaortic stenosis            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any surgical or medical condition which might      │ Any surgical or medical condition which might      │     100 │
│ significantly alter the absorption, distribution,  │ significantly alter the absorption, distribution,  │         │
│ metabolism, or excretion of study drugs,           │ metabolism, or excretion of study drugs,           │         │
│ including, but not limited to, any of the          │ including, but not limited to, any of the          │         │
│ following: History of active inflammatory bowel    │ following: History of active inflammatory bowel    │         │
│ disease during the 12 months. Active duodenal or   │ disease during the 12 months. Active duodenal or   │         │
│ gastric ulcers during the 3 months. Evidence of    │ gastric ulcers during the 3 months. Evidence of    │         │
│ hepatic disease as determined by any one of the    │ hepatic disease as determined by any one of the    │         │
│ following: aspartate aminotransferase or alanine   │ following: aspartate aminotransferase or alanine   │         │
│ aminotransferase values exceeding 2x upper limit   │ aminotransferase values exceeding 2x upper limit   │         │
│ of normal, history of hepatic encephalopathy,      │ of normal, history of hepatic encephalopathy,      │         │
│ history of oesophageal varices, or history of      │ history of oesophageal varices, or history of      │         │
│ porto-caval shunt. Current treatment with          │ porto-caval shunt. Current treatment with          │         │
│ cholestyramine or colestipol resins                │ cholestyramine or colestipol resins                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Type B natriuretic peptide (BNP) \>150 pg/ml (or   │ Type B natriuretic peptide (BNP) >150 pg/ml (or    │      98 │
│ pro-BNP \[N-terminal-proBNP\] ≥ 600 pg / ml) or if │ pro-BNP [N-terminal-proBNP] = 600 pg / ml) or if   │         │
│ the patient was hospitalized for cardiac           │ the patient was hospitalized for cardiac           │         │
│ decompensation within the preceding 12 months, BNP │ decompensation within the preceding 12 months, BNP │         │
│ \>100 pg/ml (or N-terminal-proBNP ≥ 400 pg / ml)   │ >100 pg/ml (or N-terminal-proBNP = 400 pg / ml)    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum potassium \>5.4 mmol/L                       │ Serum potassium >5.4 mmol/L                        │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Symptomatic patients with heart failure (men and   │ Symptomatic patients with heart failure (men and   │      99 │
│ women) aged \>18 years                             │ women) aged >18 years                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Left ventricular ejection fraction \<35%           │ Left ventricular ejection fraction <35%            │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Estimated glomerular filtration rate (eGFR) \<30%  │ Estimated glomerular filtration rate (eGFR) <30%   │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of any other disease with a life          │ Presence of any other disease with a life          │      99 │
│ expectancy of \<5 years                            │ expectancy of <5 years                             │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                    │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Symptomatic patients with heart failure (men and │      43 │
│                                   │ women) aged >18 years                            │         │
╘═══════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.5
OverAll Ratio: 98.25
